Research

Help Improve rehabilitation services by taking this survey

For a number of years we have mentioned the possibility of a new drug called Alemtuzumab being a potential new treatment for people with MS. On 12 June 2012 the makers, Genzyme, announced that the company has made an official application to the Food and Drugs Administration (FDA) in the US and the European Medicines Agency (EMA).

Fingolimod, under the trade name Gilenya, the first oral drug therapy for the treatment of MS, is now available under the direction of a neurologist. Gilenya is licensed as a second line therapy, making it suitable for people that have failed on conventional first line therapies or those individuals with highly active MS.

The HSE to now fund the oral therapy

An Irish company specialising in laboratory equipment, Chemical Systems Control, has donated high-tech equipment to NUI Galway to help in the battle against multiple sclerosis.

The chief regulatory body in the USA warns people with MS to be cautious about undergoing CCSVI treatment

The Neurological Alliance of Ireland (NAI) and Care Alliance are carrying out a survey of carers of people with neurological conditions. By sharing your experiences, you will help to increase understanding of the challenges faced by this group of carers.

You can complete the survey online by going to https://www.surveymonkey.com/s/neurologicalcarers

The closing date for completing the survey is Monday, 21st May 2012. The results will be published during Carers Week this June.

For more information on Carers Week 2012, go to www.carersweek.ie

The NAI is an umbrella group of over 30 neurological charities and Care Alliance is the national umbrella for organisations representing family carers.

MSIF has launched a new survey about the process of getting a diagnosis of MS.

People with MS refused treatments...